Ep14: Michael Gilman

Episode Summary

Executive Summary: Michael Gilman traces a nonlinear path from Canadian upbringing and academic biochemistry to becoming a repeat biotech entrepreneur. He explains how strong science, team-based drug development, and disciplined risk reduction led him to found and exit companies like Stromatics and Padlock, while shaping his current roles at Arrakis and Obsidian.

Main Topics: Early life, identity, and scientific curiosity (Priority: 4/5): Gilman describes growing up in Winnipeg, moving between Canada and California, and arriving at MIT with an early interest in geophysics before switching to biology after discovering he preferred biology’s complexity and relevance. Academic training that shaped his scientific worldview (Priority: 5/5): At MIT, Berkeley, and in Bob Weinberg’s lab, Gilman built deep biochemistry skills and developed an interest in cancer biology, signal transduction, and transcriptional regulation, especially around the FOS gene. Why biotech industry appealed more than academia (Priority: 5/5): He contrasts academia’s fragmented incentives with industry’s collaborative, team-oriented structure and richer data flow, arguing that drug discovery offered a more integrated and energizing way to do science. Lessons from failure, firing, and non-competes (Priority: 5/5): Gilman recounts being fired from Ariad and later Biogen, then sued over a non-compete, using these experiences to emphasize adaptability, boss selection, and the reality that scientific and business roles are vulnerable to organizational change. Entrepreneurship at Stromatics: de-risking fibrosis (Priority: 5/5): At Stromatics, he describes a strategy of separating biological and clinical hypotheses to show antifibrotic activity with less capital before a costly phase 3 trial, which helped Biogen eventually acquire the company. Padlock and the value of finding the right buyer (Priority: 4/5): Gilman explains how Padlock’s PAD-enzyme program was thought to be a biology story but was actually attractive to BMS because of the chemistry package his team had built, underscoring that value depends on what a buyer needs. Running two companies in parallel (Priority: 3/5): He says he can manage Arrakis and Obsidian simultaneously because of bandwidth, strong teams, and his belief that life is a set of moments best spent on interesting, fun science.

Key Arguments: Academic science trained him deeply, but industry better matched his preference for team-based execution, rapid data generation, and shared problem-solving. Failures and firings were formative; they taught him resilience, the importance of choosing managers carefully, and the need to recognize when to stop fighting unwinnable battles. Biotech investing and company-building should be driven by systematic risk reduction: each new dollar should de-risk the program more than the last. A good company strategy must distinguish biological, clinical, and commercial hypotheses so trials answer one clear question at a time. Stromatics succeeded because it reframed fibrosis development into a testable biological question rather than an all-or-nothing clinical bet. Padlock succeeded because the team found the right buyer and brought valuable chemistry rather than just compelling biology. He is effective as an entrepreneur because he finds the science compelling, likes the people, and values the quality of day-to-day work over long-term grand plans.

Data Points: Age when became entrepreneur: around 50 - Gilman says he entered entrepreneurship relatively late in life after leaving Biogen. US citizenship age: 62 or 63 - He says he became a U.S. citizen only about a year and a half before the interview and voted for the first time shortly after. MIT start year: 1972 - He began undergraduate studies at MIT in 1972. Postdoc start year: 1983 - He started in Bob Weinberg’s lab at the Whitehead Institute in 1983. Cold Spring Harbor tenure: 7 or 8 years - He says he stayed at Cold Spring Harbor for roughly seven to eight years as an independent investigator. Biogen scientific organization size: about 450 scientists - He describes Biogen as having around 450 scientists when he left. Biogen downsizing: about one-third of research organization - He says he was asked to help lay off roughly one-third of the research staff after Tysabri was pulled. Stromatics capital risk reduction: $25 million - He says the company believed it could prove the antifibrotic concept on about $25 million of capital. Stromatics value creation: 10x - He says a positive result would create an asset worth roughly 10 times the invested capital. Time to test clinical hypothesis: could require phase 3 / $200–300 million - He contrasts the cheaper biological test with the much more expensive full clinical development path Biogen otherwise faced. RA antibody prevalence: 75% - He notes that about 75% of rheumatoid arthritis patients make antibodies to citrullinated proteins. RA antibody specificity: 98% specific - He says those antibodies are about 98% specific for rheumatoid arthritis. Lead-time before RA symptoms: 10 years - He says these antibodies can be detected up to 10 years before clinical disease appears. Stromatics/Biogen acquisition timing: before first patient dosed - Biogen acquired the company before the relevant IPF trial had begun dosing patients.

Pivotal Quotes: "I think you should take this job because you could do more than you're doing now." — David Baltimore: Advice that convinced Gilman to leave academia for industry and helped trigger his first major entrepreneurial transition. "I'm a data junkie. Bottom line is I'm basically a data junkie." — Michael Gilman: Explains why he prefers biotech teams and programs that generate frequent, actionable data. "Life is nothing more than a collection of moments, right? And you should maximize the quality of those moments." — Michael Gilman: His explanation for why he is content running two companies and prioritizes engaging work over long-term planning.

Implications: The interview shows that biotech success often comes from rigorous risk framing, strong teams, and flexibility when plans change. It also suggests late-career entrepreneurship can be an advantage if paired with deep science, humility, and a bias for learning.